




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Hot Topic

Chloroquine for the 2019 novel coronavirus SARS-CoV-2



A movement to reposition drugs has been initiated in recent years [1]. In this strategy, it is important to use drugs that have been proven to be harmless and whose pharmacokinetics and optimal dosage are well known. In the current episode of novel coronavirus (SARS-CoV-2) emergence [2], we find a spectacular example of possible repositioning of drugs, particularly chloroquine. We had 20 years ago proposed to systematically test chloroquine in viral infections because it had been shown to be effective *in vitro* against a broad range of viruses [3,4]. This drug has multiple activities, one of which is to alkalinise the phagolysosome, which hampers the low-pH-dependent steps of viral replication, including fusion and uncoating [4]. Other mechanisms of antiviral activity are poorly explained [5].

At the time of the severe acute respiratory syndrome (SARS)-associated coronavirus epidemic [6] in 2003, several molecules were tested to assess their effectiveness against this virus. Among these, teicoplanin [7], an antistaphylococcal agent, had proven efficacy *in vitro*, and this was also the case for chloroquine, at a 50% effective concentration (EC₅₀) of approximately 8 µM, and when added to the cell culture either before or after exposure to the virus [5,8–10]. These findings ended up being forgotten because of the disappearance of SARS for reasons that are neither clear nor explained [11]. The novel coronavirus currently isolated in China has been, with staggering speed, evaluated regarding its sensitivity to already used drugs [12]. Thus, the new antiviral drug remdesivir [13] as well as chloroquine, at an EC₅₀ of 1.1 µM, were found to be effective in preventing replication of this virus [12]. Chloroquine is perhaps one of the most prescribed drugs in the world [14,15]. As a matter of fact, all Europeans visiting malaria-endemic geographic areas for decades received chloroquine prophylaxis and continued it for 2 months after their return. In addition, local residents took chloroquine continuously, and treatment of malaria has long been based on this drug. In addition, hydroxychloroquine has been used for decades at much higher doses (up to 600 mg/day) to treat autoimmune diseases [16]. It is difficult to find a product that currently has a better established safety profile than chloroquine. Furthermore, its cost is negligible. Hence, its possible use both in prophylaxis in people exposed to the novel coronavirus and as a curative treatment will probably be promptly evaluated by our Chinese colleagues. If clinical data confirm the biological results, the novel coronavirus-associated disease will have become one of the simplest and cheapest to treat and prevent among infectious respiratory diseases.

Funding: This work was supported by the French Government under the 'Investments for the Future' program managed by the

National Agency for Research (ANR) [Méditerranée-Infection 10-IAHU-03]. The funding sources had no role in the preparation, review or approval of the manuscript.

Competing interests: None declared.

Ethical approval: Not required.

Philippe Colson, Jean-Marc Rolain, Didier Raoult*
Aix-Marseille Université, Institut de Recherche pour le
Développement (IRD), Assistance Publique-Hôpitaux de Marseille
(AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France
IHU Méditerranée Infection, 19–21 boulevard Jean Moulin, 13005
Marseille, France

*Corresponding author. Present address: IHU Méditerranée
Infection, 19–21 boulevard Jean Moulin, 13005 Marseille, France.
Tel.: +33 4 13 732 401; fax: +33 4 13 732 402.
E-mail address: didier.raoult@gmail.com (D. Raoult)

Received 11 February 2020
Accepted 11 February 2020

References

- [1] Mullard A. Drug repurposing programmes get lift off. *Nat Rev Drug Discov* 2012;11:505–6. doi:10.1038/nrd3776.
- [2] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020 Feb 3 [Epub ahead of print]. doi:10.1038/s41586-020-2012-7.
- [3] Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. *Lancet Infect Dis* 2006;6:67–9. doi:10.1016/S1473-3099(06)70361-9.
- [4] Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents* 2007;30:297–308. doi:10.1016/j.ijantimicag.2007.05.015.
- [5] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology* 2005;269:69–77. doi:10.1016/j.virol.2005.02.009.
- [6] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 2003;348:1953–66. doi:10.1056/NEJMoa030781.
- [7] Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. *Antiviral Res* 2006;72:20–33. doi:10.1016/j.antiviral.2006.03.005.
- [8] Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem Biophys Res Commun* 2004;323:264–8. doi:10.1016/j.bbrc.2004.08.085.

- [9] Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir Chem Chemother* 2006;17:275–84. doi:[10.1177/095632020601700505](https://doi.org/10.1177/095632020601700505).
- [10] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother* 2014;58:4875–84. doi:[10.1128/AAC.03011-14](https://doi.org/10.1128/AAC.03011-14).
- [11] Yu IT, Qiu H, Tse LA, Wong TW. Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. *Clin Infect Dis* 2014;58:683–6. doi:[10.1093/cid/cit797](https://doi.org/10.1093/cid/cit797).
- [12] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020 Feb 4 [Epub ahead of print]. doi:[10.1038/s41422-020-0282-0](https://doi.org/10.1038/s41422-020-0282-0).
- [13] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *mBio* 2018;9 pii: e00221-18. doi:[10.1128/mBio.00221-18](https://doi.org/10.1128/mBio.00221-18).
- [14] White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. *Lancet* 2014;383:723–35. doi:[10.1016/S0140-6736\(13\)60024-0](https://doi.org/10.1016/S0140-6736(13)60024-0).
- [15] Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. *J Antimicrob Chemother* 2015;70:1608–21. doi:[10.1093/jac/dkv018](https://doi.org/10.1093/jac/dkv018).
- [16] Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. *Nat Rev Nephrol* 2011;7:718–29. doi:[10.1038/nrneph.2011.150](https://doi.org/10.1038/nrneph.2011.150).